Skip to content

The effect of Elaeagnus angustifolia flower to improvement of female sexual dysfunction

Compare the effect of Elaeagnus angustifolia flower capsule and sildenafil citrate tablet on female sexual dysfunction and anxiety in married 18-40 years old .

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201205219818N1
Enrollment
126
Registered
2012-06-07
Start date
2012-06-09
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: female sexual dysfunction. Condition 2: anxiety. Behavioural syndromes associated with physiological disturbances and physical factors Neurotic, stress-related and somatoform disorders

Interventions

Intervention 1: intervention with Elaeagnus angustifolia flower capsule , for each person 4.5g in day BID (each 12 hours, 2 capsuls) for 35 days. Intervention 2: intervention with sildenafil citrate
Treatment - Drugs
Placebo
intervention with Elaeagnus angustifolia flower capsule , for each person 4.5g in day BID (each 12 hours, 2 capsuls) for 35 days
intervention with sildenafil citrate tablet 50 mg - one hour before having intercourse for 35 days

Sponsors

Vice chancellor for Research, Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: willingness to participate; married woman with age between 18-40 ; having score28 and below of it from Female Sexual Function Index; not pregnant; not having breast feeding; No history of heart disease and vascular disease (the patient's medical records); No history of uncontrolled hypertension and hypotension; Not taking any medications that affect sexual function (specially common antidepressant). Exclusion criteria:taking hormone pills particulary OCP; taking alchohl or tobacco; history of active peptic ulcer disease ; history of headaches including migraines; history of dysparunia or vaginismus.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Female sexual dysfunction. Timepoint: At the start of intervention- After intervention. Method of measurement: Female Sexual Function Index Questionnaire.;Anxiety. Timepoint: At the start of intervention- After intervention. Method of measurement: Spielberger questionnaire.

Secondary

MeasureTime frame
Improvement of sexual function. Timepoint: During the study and after completion of it. Method of measurement: Female Sexual Function Index Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Akbarzadeh

Fatemeh College of Nursing And Midwifery,Shiraz University of Medical Sciences

akbarzadehmarzieh@ yahoo.com+98 71 1647 4252

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026